FDA Getting Reg Slashing Directive In Trump Executive Order
Executive Summary
Draft order wants "comprehensive review" to find regulations that that "unnecessarily increases expenses" for patients, researchers, and manufacturers.
You may also be interested in...
FDA Soliciting Broad Range Of Comments From Industry On Regulatory Reform
FDA is addressing regulatory reform as part of President Trump's "two-for-one" executive order, and seeks industry comments to supplement the effort.
Policy People In The News: Neomi Rao Confirmed To Head White House Reg Office
Former US FDA global regulator Howard Sklamberg joins law firm Akin Gump; PhRMA adds two VPS; more changes in personnel.
Insulin Market Competition: Payers Watching FDA 'Transition' Policy
FDA policies around the upcoming regulatory reclassification of insulins as biologics may impact payers' ability to leverage competition and pricing in the market, Express Scripts suggests.